Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECT trial: EOX versus Docetaxel + Oxaliplatin in advanced gastro-oesophageal cancer
2006-003332-29Phase 2Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Feb 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of epirubicin, docetaxel, oxaliplatin and capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and adenocarcinoma of the esophagus (EAC) (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Objective response rate. Started Feb 2007; status: terminated.
02
Drugs
epirubicindocetaxeloxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaadenocarcinoma of the esophagus (EAC)
Beyond the preview
Go deeper on 2006-003332-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003332-29.